ut-logo website  
Register and login to access premium content
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

5-Alpha reductase inhibitors in patients on active surveillance: Do the benefits outweigh the risk? - Abstract

Prostate cancer (PCa) is a slow, progressive disease.

Prostate specific antigen testing, screening, and aggressive case identification has made PCa the most frequently diagnosed cancer. Concerns regarding overdiagnosis and overtreatment flourish on a large scale. In order to avoid overtreatment for those in whom therapeutic intervention is not required, active surveillance for eligible patients with the use of 5-alpha reductase can be considered a safe and a promising approach to delay the progression of the disease with minimal side effects.

Written by:
Al Edwan G, Fleshner N.   Are you the author?
Division of Urology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada. This email address is being protected from spambots. You need JavaScript enabled to view it.

Reference: Curr Urol Rep. 2013 Apr 12. Epub ahead of print.
doi: 10.1007/s11934-013-0324-y


PubMed Abstract
PMID: 23579402

UroToday.com Prostate Cancer Section